UBS Group
IMNN icon

UBS Group’s Imunon IMNN Stock Holding History

UBS Group’s Portfolio IMNN Stock Details IMNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.69K Sell
575
-1,022
-64% -$3.37K ﹤0.01% 9464
2025
Q4 		$6.08K Sell
1,597
-9,207
-85% -$39.4K ﹤0.01% 8588
2025
Q3 		$55.4K Buy
10,804
+9,628
+819% +$64.3K ﹤0.01% 7488
2025
Q2 		$12.3K Buy
1,176
+1,174
+58,700% +$16K ﹤0.01% 8743
2025
Q1 		$23 Hold
2
– – ﹤0.01% 10078
2024
Q4 		$21 Hold
2
– – ﹤0.01% 9774
2024
Q3 		$22 Sell
2
-993
-100% -$15.7K ﹤0.01% 9296
2024
Q2 		$15.1K Buy
995
+993
+49,650% +$17.5K ﹤0.01% 7484
2024
Q1 		$34 Sell
2
-450
-100% -$4.28K ﹤0.01% 8968
2023
Q4 		$4.01K Buy
452
+450
+22,500% +$5.49K ﹤0.01% 7916
2023
Q3 		$21 Sell
2
-18
-90% -$281 ﹤0.01% 9114
2023
Q2 		$337 Sell
20
-99
-83% -$1.64K ﹤0.01% 8296
2023
Q1 		$1.93K Buy
119
+52
+78% +$1K ﹤0.01% 8623
2022
Q4 		$1.18K Buy
67
+49
+272% +$943 ﹤0.01% 9931
2022
Q3 		$0 Hold
18
– – ﹤0.01% 10610
2022
Q2 		$0 Sell
18
-3
-14% -$110 ﹤0.01% 10600
2022
Q1 		$1K Sell
21
-64
-75% -$5.02K ﹤0.01% 9879
2021
Q4 		$9K Sell
85
-61
-42% -$9.5K ﹤0.01% 8909
2021
Q3 		$26K Buy
146
+29
+25% +$6.02K ﹤0.01% 6885
2021
Q2 		$29K Buy
117
+36
+44% +$8.51K ﹤0.01% 6973
2021
Q1 		$22K Hold
81
– – ﹤0.01% 7288
2020
Q4 		$12K Sell
81
-58
-42% -$6.95K ﹤0.01% 7344
2020
Q3 		$20K Buy
139
+120
+632% +$30.3K ﹤0.01% 6308
2020
Q2 		$14K Sell
19
-12
-39% -$5.2K ﹤0.01% 6788
2020
Q1 		$5K Sell
31
-3
-9% -$752 ﹤0.01% 7291
2019
Q4 		$11K Buy
34
+14
+70% +$4.25K ﹤0.01% 7233
2019
Q3 		$6K Sell
20
-2
-9% -$684 ﹤0.01% 7410
2019
Q2 		$8K Sell
22
-41
-65% -$16.7K ﹤0.01% 7187
2019
Q1 		$25K Buy
63
+12
+24% +$4.97K ﹤0.01% 6104
2018
Q4 		$14K Sell
51
-2
-4% -$830 ﹤0.01% 7040
2018
Q3 		$29K Buy
53
+19
+56% +$10.5K ﹤0.01% 6565
2018
Q2 		$20K Buy
34
+8
+31% +$3.97K ﹤0.01% 6696
2018
Q1 		$12K Buy
26
+16
+160% +$7.7K ﹤0.01% 6759
2017
Q4 		$5K Sell
10
-104
-91% -$59K ﹤0.01% 7376
2017
Q3 		$33K Sell
114
-57
-33% -$17.6K ﹤0.01% 6096
2017
Q2 		$69K Buy
171
+167
+4,175% +$107K ﹤0.01% 5431
2017
Q1 		$3K Hold
4
– – ﹤0.01% 7180
2016
Q4 		$3K Buy
4
+2
+100% +$4.57K ﹤0.01% 7412
2016
Q3 		$7K Hold
2
– – ﹤0.01% 6977
2016
Q2 		$8K Hold
2
– – ﹤0.01% 6896
2016
Q1 		$9K Sell
2
-2
-50% -$7.6K ﹤0.01% 6717
2015
Q4 		$23K Buy
4
+1
+33% +$5.13K ﹤0.01% 6603
2015
Q3 		$14K Buy
3
+1
+50% +$5.97K ﹤0.01% 7017
2015
Q2 		$11K Buy
2
+1
+100% +$7.1K ﹤0.01% 7391
2015
Q1 		$6K Sell
1
-4
-80% -$27.8K ﹤0.01% 8008
2014
Q4 		$34K Buy
+5
New +$34.7K ﹤0.01% 6962

Other funds holding IMNN

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's IMNN Position: Q1 2026 in Review

UBS Group reduced its Imunon (IMNN) stake by 64% in Q1 2026, selling an estimated $3.37K and leaving 575 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #9464.

UBS Group first reported a position in IMNN in Q4 2014 and has held it in 46 quarters since. The position peaked at $69K in Q2 2017. 19 funds tracked by Wall St. Rank hold IMNN as of Q1 2026.

  • UBS Group held 575 shares of Imunon worth $1.69K as of Q1 2026.
  • UBS Group sold 1,022 Imunon shares in Q1 2026, an estimated $3.37K.
  • Imunon made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9464 holding.
  • UBS Group first reported a position in Imunon in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Imunon position peaked at $69K in Q2 2017.
  • 19 funds tracked by Wall St. Rank held Imunon as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.